A phase Ib study to evaluate repeat doses of MIV 711 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2013
Price : $35 *
At a glance
- Drugs MIV 711 (Primary)
- Indications Osteoarthritis; Postmenopausal osteoporosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Medivir AB
- 06 Oct 2013 Results for the 7-day dosing series presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
- 22 Aug 2013 Data are being analysed and results will be presented at a scientific congress later in 2013, according to a Medivir media release.
- 05 Jun 2013 Top-line results are expected around mid-year 2013, according to a Medivir media release.